Rapid re-emergence of YMDD mutation of hepatitis B virus with hepatic decompression after lamivudine retreatment

So Young Kwon, Won Hyeok Choe, Chang Hong Lee, Jong Eun Yeon, Kwan Soo Byun

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Lamivudine has a high rate of antiviral resistance. Sequential treatment of anti-hepatitis B virus (HBV) is commonly used for lamivudine resistance. We report 4 cases of patients with rapid redetection of HBV mutants during the lamivudine retreatment. The four patients received lamivudine as an initial treatment of HBV and adefovir and lamivudine as a rescue therapy consecutively. HBV-DNA level, YMDD mutations and adefovir -resistant mutations (RFMP) were tested every 3 mo during the sequential treatment. All the patients showed YMDD mutations during the initial lamivudine therapy. After adefovir therapy for lamivudine resistance, they showed viral breakthrough. Adefovir was switched to lamivudine, however, it did not induce viral suppression at all, rather increased HBV-DNA with rapid reemergence of the YMDD mutations. All the patients had ALT flares, and hepatic decompensation occurred in two patients. After switching to adefovir combined with entecavir or lamivudine for a rescue therapy, the patients had reduction in HBV-DNA and ALT improvement. These cases demonstrated that lamivudine retreatment of patients with preexposed lamivudine resistance leads to rapid reemergence of YMDD mutation with significant viral rebounds and subsequent hepatic decompensation. Sequential administration of lamivudine in patients with a prior history of YMDD mutation should be abandoned.

Original languageEnglish
Pages (from-to)4416-4419
Number of pages4
JournalWorld Journal of Gastroenterology
Volume14
Issue number27
DOIs
Publication statusPublished - 2008 Jul 21

Fingerprint

Retreatment
Lamivudine
Decompression
Hepatitis B virus
Mutation
Liver
Therapeutics
DNA
Antiviral Agents
adefovir

Keywords

  • Adefovir dipivoxil
  • Hepatitis B
  • Lamivudine
  • Mutations

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Rapid re-emergence of YMDD mutation of hepatitis B virus with hepatic decompression after lamivudine retreatment. / Kwon, So Young; Choe, Won Hyeok; Lee, Chang Hong; Yeon, Jong Eun; Byun, Kwan Soo.

In: World Journal of Gastroenterology, Vol. 14, No. 27, 21.07.2008, p. 4416-4419.

Research output: Contribution to journalArticle

@article{dcebb49d89b14843bac691d6d636f1cb,
title = "Rapid re-emergence of YMDD mutation of hepatitis B virus with hepatic decompression after lamivudine retreatment",
abstract = "Lamivudine has a high rate of antiviral resistance. Sequential treatment of anti-hepatitis B virus (HBV) is commonly used for lamivudine resistance. We report 4 cases of patients with rapid redetection of HBV mutants during the lamivudine retreatment. The four patients received lamivudine as an initial treatment of HBV and adefovir and lamivudine as a rescue therapy consecutively. HBV-DNA level, YMDD mutations and adefovir -resistant mutations (RFMP) were tested every 3 mo during the sequential treatment. All the patients showed YMDD mutations during the initial lamivudine therapy. After adefovir therapy for lamivudine resistance, they showed viral breakthrough. Adefovir was switched to lamivudine, however, it did not induce viral suppression at all, rather increased HBV-DNA with rapid reemergence of the YMDD mutations. All the patients had ALT flares, and hepatic decompensation occurred in two patients. After switching to adefovir combined with entecavir or lamivudine for a rescue therapy, the patients had reduction in HBV-DNA and ALT improvement. These cases demonstrated that lamivudine retreatment of patients with preexposed lamivudine resistance leads to rapid reemergence of YMDD mutation with significant viral rebounds and subsequent hepatic decompensation. Sequential administration of lamivudine in patients with a prior history of YMDD mutation should be abandoned.",
keywords = "Adefovir dipivoxil, Hepatitis B, Lamivudine, Mutations",
author = "Kwon, {So Young} and Choe, {Won Hyeok} and Lee, {Chang Hong} and Yeon, {Jong Eun} and Byun, {Kwan Soo}",
year = "2008",
month = "7",
day = "21",
doi = "10.3748/wjg.14.4416",
language = "English",
volume = "14",
pages = "4416--4419",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "27",

}

TY - JOUR

T1 - Rapid re-emergence of YMDD mutation of hepatitis B virus with hepatic decompression after lamivudine retreatment

AU - Kwon, So Young

AU - Choe, Won Hyeok

AU - Lee, Chang Hong

AU - Yeon, Jong Eun

AU - Byun, Kwan Soo

PY - 2008/7/21

Y1 - 2008/7/21

N2 - Lamivudine has a high rate of antiviral resistance. Sequential treatment of anti-hepatitis B virus (HBV) is commonly used for lamivudine resistance. We report 4 cases of patients with rapid redetection of HBV mutants during the lamivudine retreatment. The four patients received lamivudine as an initial treatment of HBV and adefovir and lamivudine as a rescue therapy consecutively. HBV-DNA level, YMDD mutations and adefovir -resistant mutations (RFMP) were tested every 3 mo during the sequential treatment. All the patients showed YMDD mutations during the initial lamivudine therapy. After adefovir therapy for lamivudine resistance, they showed viral breakthrough. Adefovir was switched to lamivudine, however, it did not induce viral suppression at all, rather increased HBV-DNA with rapid reemergence of the YMDD mutations. All the patients had ALT flares, and hepatic decompensation occurred in two patients. After switching to adefovir combined with entecavir or lamivudine for a rescue therapy, the patients had reduction in HBV-DNA and ALT improvement. These cases demonstrated that lamivudine retreatment of patients with preexposed lamivudine resistance leads to rapid reemergence of YMDD mutation with significant viral rebounds and subsequent hepatic decompensation. Sequential administration of lamivudine in patients with a prior history of YMDD mutation should be abandoned.

AB - Lamivudine has a high rate of antiviral resistance. Sequential treatment of anti-hepatitis B virus (HBV) is commonly used for lamivudine resistance. We report 4 cases of patients with rapid redetection of HBV mutants during the lamivudine retreatment. The four patients received lamivudine as an initial treatment of HBV and adefovir and lamivudine as a rescue therapy consecutively. HBV-DNA level, YMDD mutations and adefovir -resistant mutations (RFMP) were tested every 3 mo during the sequential treatment. All the patients showed YMDD mutations during the initial lamivudine therapy. After adefovir therapy for lamivudine resistance, they showed viral breakthrough. Adefovir was switched to lamivudine, however, it did not induce viral suppression at all, rather increased HBV-DNA with rapid reemergence of the YMDD mutations. All the patients had ALT flares, and hepatic decompensation occurred in two patients. After switching to adefovir combined with entecavir or lamivudine for a rescue therapy, the patients had reduction in HBV-DNA and ALT improvement. These cases demonstrated that lamivudine retreatment of patients with preexposed lamivudine resistance leads to rapid reemergence of YMDD mutation with significant viral rebounds and subsequent hepatic decompensation. Sequential administration of lamivudine in patients with a prior history of YMDD mutation should be abandoned.

KW - Adefovir dipivoxil

KW - Hepatitis B

KW - Lamivudine

KW - Mutations

UR - http://www.scopus.com/inward/record.url?scp=55949099628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55949099628&partnerID=8YFLogxK

U2 - 10.3748/wjg.14.4416

DO - 10.3748/wjg.14.4416

M3 - Article

VL - 14

SP - 4416

EP - 4419

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 27

ER -